DMAC - DiaMedica gains on positive mid-stage trial data for lead drug in preeclampsia
2025-07-17 11:14:46 ET
More on DiaMedica Therapeutics
- DiaMedica Therapeutics Inc. (DMAC) Q1 2025 Earnings Call Transcript
- DiaMedica Therapeutics to be included in the Russell 2000 and 3000 indexes
- DiaMedica targets preeclampsia Phase 2 dose selection and ReMEDy2 interim analysis in H1 2026 as enrollment momentum builds
- Seeking Alpha’s Quant Rating on DiaMedica Therapeutics
- Historical earnings data for DiaMedica Therapeutics